Endometriosis Market
Endometriosis Market Infographics

Endometriosis Market

Endometriosis is a condition marked by the uncontrolled expansion of tissue that resembles endometrium outside the uterus. When a woman is not pregnant, endometrial tissue ordinarily borders the uterus and thickens and breaks down as part of the monthly cycle. The abnormal growths, or lesions, can appear anywhere in the body, although they typically appear on or near the reproductive organs, the bowels, or the bladder.

Endometriosis Epidemiology Segmentation in the 7MM from 2019 to 2032

  • Prevalent Population
  • Age-specific Prevalent Population
  • Diagnosed and Treatable Cases
  • SWOT Analysis

Endometriosis Strengths

  • Increasing awareness and development to understand the diversity of the disease might improve the diagnosis of Endometriosis, thereby resulting in a lucrative market opportunity.

Endometriosis Opportunities

  • The current treatment options only focus on palliative treatment rather than cure, which opens a platform of new therapies to boost the market of Endometriosis.

Endometriosis Emerging Drugs and Key Companies

  • Linzagolix (OBE2109): ObsEva
  • Relugolix combination tablet: Myovant Sciences
  • Eliapixant: Bayer
  • Gefapixant (MK-7264) : Merck
  • MT-2990: Mitsubishi Tanabe Pharma Development America